These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 25366268)
41. Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate. Kobayakawa T; Kojima T; Takahashi N; Hayashi M; Yabe Y; Kaneko A; Shioura T; Saito K; Hirano Y; Kanayama Y; Miyake H; Asai N; Funahashi K; Hirabara S; Hanabayashi M; Asai S; Ishiguro N Mod Rheumatol; 2015 Mar; 25(2):251-6. PubMed ID: 25211402 [TBL] [Abstract][Full Text] [Related]
42. Exploring TNFi drug-levels and anti-drug antibodies during tapering among patients with inflammatory arthritis: secondary analyses from the randomised BIODOPT trial. Uhrenholt L; Sørensen MER; Lauridsen KB; Duch K; Dreyer L; Christensen R; Hauge EM; Loft AG; Rasch MNB; Horn HC; Taylor PC; Nielsen KR; Kristensen S Rheumatol Int; 2024 Oct; 44(10):1897-1908. PubMed ID: 39043980 [TBL] [Abstract][Full Text] [Related]
43. Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs. Pappas DA; Hooper MM; Kremer JM; Reed G; Shan Y; Wenkert D; Greenberg JD; Curtis JR Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1671-8. PubMed ID: 26018115 [TBL] [Abstract][Full Text] [Related]
44. A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes. Bouman CAM; van der Maas A; van Herwaarden N; Sasso EH; van den Hoogen FHJ; den Broeder AA Rheumatology (Oxford); 2017 Jun; 56(6):973-980. PubMed ID: 28339738 [TBL] [Abstract][Full Text] [Related]
45. Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis. Cannon GW; DuVall SL; Haroldsen CL; Caplan L; Curtis JR; Michaud K; Mikuls TR; Reimold A; Collier DH; Joseph GJ; Harrison DJ; Sauer BC Adv Ther; 2016 Aug; 33(8):1347-59. PubMed ID: 27352377 [TBL] [Abstract][Full Text] [Related]
46. Optimizing withdrawal strategies for anti-TNF-α therapies in rheumatoid arthritis. Venetsanopoulou AI; Voulgari PV; Drosos AA Expert Opin Biol Ther; 2024 Aug; 24(8):815-825. PubMed ID: 39051615 [TBL] [Abstract][Full Text] [Related]
47. Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis. Chastek B; Becker LK; Chen CI; Mahajan P; Curtis JR J Med Econ; 2017 May; 20(5):464-473. PubMed ID: 28010149 [TBL] [Abstract][Full Text] [Related]
48. Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy. Wei W; Knapp K; Wang L; Chen CI; Craig GL; Ferguson K; Schwartzman S Adv Ther; 2017 Aug; 34(8):1936-1952. PubMed ID: 28674959 [TBL] [Abstract][Full Text] [Related]
49. The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis. Hernández MV; Sanmartí R; Cañete JD Expert Opin Drug Saf; 2016 May; 15(5):613-24. PubMed ID: 26927029 [TBL] [Abstract][Full Text] [Related]
50. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA. Chastek B; Chen CI; Proudfoot C; Shinde S; Kuznik A; Wei W Adv Ther; 2017 Nov; 34(11):2422-2435. PubMed ID: 29039054 [TBL] [Abstract][Full Text] [Related]
51. Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission? Alivernini S; Tolusso B; Petricca L; Bui L; Di Sante G; Peluso G; Benvenuto R; Fedele AL; Federico F; Ferraccioli G; Gremese E Ann Rheum Dis; 2017 Jul; 76(7):1228-1236. PubMed ID: 28119289 [TBL] [Abstract][Full Text] [Related]
52. The influence of comorbidities on the efficacy of tumour necrosis factor inhibitors, and the effect of tumour necrosis factor inhibitors on comorbidities in rheumatoid arthritis: report from a National Consensus Conference. Conti F; Atzeni F; Massaro L; Chiara Gerardi M; Gremese E; Passiu G; Carletto A; Malavolta N; Foti R; Ramonda R; Sarzi-Puttini P Rheumatology (Oxford); 2018 Oct; 57(57 Suppl 7):vii11-vii22. PubMed ID: 30289537 [TBL] [Abstract][Full Text] [Related]
53. Comparing a tapering strategy to the standard dosing regimen of TNF inhibitors in rheumatoid arthritis patients with low disease activity. Plasencia C; Wolbink G; Krieckaert CL; Kneepkens EL; Turk S; Jurado T; Martínez-Feito A; Navarro-Compán V; Bonilla G; Villalba A; Peiteado D; Nuño L; Martín-Mola E; Nurmohamed MT; van der Kleij D; Rispens T; Pascual-Salcedo D; Balsa A Clin Exp Rheumatol; 2016; 34(4):655-62. PubMed ID: 27214767 [TBL] [Abstract][Full Text] [Related]
54. Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial. Manders SH; Kievit W; Adang E; Brus HL; Moens HJ; Hartkamp A; Hendriks L; Brouwer E; Visser H; Vonkeman HE; Hendrikx J; Jansen TL; Westhovens R; van de Laar MA; van Riel PL Arthritis Res Ther; 2015 May; 17(1):134. PubMed ID: 25997746 [TBL] [Abstract][Full Text] [Related]
55. Comparative effectiveness of treatment options after conventional DMARDs failure in rheumatoid arthritis. Sung YK; Cho SK; Kim D; Choi CB; Won S; Bang SY; Cha HS; Choe JY; Chung WT; Hong SJ; Jun JB; Kim HA; Kim J; Kim SK; Kim TH; Lee HS; Lee J; Lee J; Lee SS; Lee SW; Lee YA; Nah SS; Suh CH; Yoo DH; Yoon BY; Bae SC; Rheumatol Int; 2017 Jun; 37(6):975-982. PubMed ID: 28132102 [TBL] [Abstract][Full Text] [Related]
56. Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission. El Miedany Y; El Gaafary M; Youssef S; Ahmed I; Bahlas S; Hegazi M; Nasr A Clin Rheumatol; 2016 Dec; 35(12):2915-2923. PubMed ID: 27658417 [TBL] [Abstract][Full Text] [Related]
57. One-Year Tuberculosis Risk in Rheumatoid Arthritis Patients Starting Their First Tumor Necrosis Factor Inhibitor Therapy from 2008 to 2012 in Taiwan: A Nationwide Population-Based Cohort Study. Lim CH; Lin CH; Chen DY; Chen YM; Chao WC; Liao TL; Chen HH PLoS One; 2016; 11(11):e0166339. PubMed ID: 27832150 [TBL] [Abstract][Full Text] [Related]
58. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study. Raaschou P; Frisell T; Askling J; Ann Rheum Dis; 2015 Dec; 74(12):2137-43. PubMed ID: 25107559 [TBL] [Abstract][Full Text] [Related]
59. Tocilizumab in patients with active rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs or tumor necrosis factor inhibitors: subanalysis of Spanish results of an open-label study close to clinical practice. Álvaro-Gracia JM; Fernández-Nebro A; García-López A; Guzmán M; Blanco FJ; Navarro FJ; Bustabad S; Armendáriz Y; Román-Ivorra JA; Reumatol Clin; 2014; 10(2):94-100. PubMed ID: 24099961 [TBL] [Abstract][Full Text] [Related]
60. Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy. Chang CY; Meyer RM; Reiff AO Arthritis Care Res (Hoboken); 2015 May; 67(5):658-66. PubMed ID: 25220674 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]